These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2886989

  • 1. Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration.
    Magnusson O, Mohringe B, Thorell G, Lake-Bakaar DM.
    Pharmacol Toxicol; 1987 May; 60(5):368-73. PubMed ID: 2886989
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of the novel antipsychotic agent remoxipride on dopamine and noradrenaline turnover in the rat brain.
    Magnusson O, Fowler CJ.
    Pharmacol Toxicol; 1989 Oct; 65(4):295-8. PubMed ID: 2573899
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation.
    Magnusson O, Mohringe B, Fowler CJ.
    J Neural Transm; 1987 Oct; 69(3-4):163-77. PubMed ID: 2957465
    [Abstract] [Full Text] [Related]

  • 4. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.
    Magnusson O, Fowler CJ, Köhler C, Ogren SO.
    Neuropharmacology; 1986 Feb; 25(2):187-97. PubMed ID: 2939362
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain.
    Hall H, Sällemark M.
    Pharmacol Toxicol; 1987 May; 60(5):359-63. PubMed ID: 2886988
    [Abstract] [Full Text] [Related]

  • 7. Biochemical pharmacology of the atypical neuroleptic remoxipride.
    Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K.
    Acta Psychiatr Scand Suppl; 1990 May; 358():27-36. PubMed ID: 1978484
    [Abstract] [Full Text] [Related]

  • 8. Neurochemical effects of prolonged treatment with remoxipride as assessed by intracerebral microdialysis in freely moving rats.
    Georgieva J, Mohringe B, Magnusson O.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Nov; 18(7):1187-201. PubMed ID: 7846288
    [Abstract] [Full Text] [Related]

  • 9. Effect of long-term dosing with tiapride on brain dopamine receptors and metabolism in rats. Comparative study with sulpiride and haloperidol.
    Satoh H, Kuwaki T, Shirakawa K, Kohjimoto Y, Ono T, Shibayama F, Nomura Y.
    Jpn J Pharmacol; 1987 Aug; 44(4):393-403. PubMed ID: 3682405
    [Abstract] [Full Text] [Related]

  • 10. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain.
    Ericson H, Ross SB.
    Eur J Pharmacol; 1992 Jun 05; 226(2):157-61. PubMed ID: 1353452
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain.
    Magnusson O, Fowler CJ, Mohringe B, Wijkström A, Ogren SO.
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr 05; 337(4):379-84. PubMed ID: 2900472
    [Abstract] [Full Text] [Related]

  • 12. Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.
    Köhler C, Radesäter AC, Karlsson-Boethius G, Bryske B, Widman M.
    J Neural Transm Gen Sect; 1992 Apr 05; 87(1):49-62. PubMed ID: 1531593
    [Abstract] [Full Text] [Related]

  • 13. Neuropharmacological and behavioural properties of remoxipride in the rat.
    Ogren SO, Florvall L, Hall H, Magnusson O, Angeby-Möller K.
    Acta Psychiatr Scand Suppl; 1990 Apr 05; 358():21-6. PubMed ID: 1978483
    [Abstract] [Full Text] [Related]

  • 14. Chronic neuroleptic treatment does not suppress the dynamic characteristics of the dopaminergic receptor D2 system.
    Andia I, Zumarraga M, Retuerto F, Zamalloa I, Davila R.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan 05; 18(1):181-91. PubMed ID: 7906895
    [Abstract] [Full Text] [Related]

  • 15. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists.
    Pellissier G, Demenge P.
    J Cardiovasc Pharmacol; 1991 Oct 05; 18(4):548-55. PubMed ID: 1724532
    [Abstract] [Full Text] [Related]

  • 16. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
    Gerlach J, Casey DE.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Oct 05; 14(1):103-12. PubMed ID: 1967845
    [Abstract] [Full Text] [Related]

  • 17. Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing.
    Csernansky JG, Bellows EP, Barnes DE, Lombrozo L.
    Psychopharmacology (Berl); 1990 Oct 05; 101(4):519-24. PubMed ID: 2388975
    [Abstract] [Full Text] [Related]

  • 18. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO, Hall H, Köhler C, Magnusson O, Florvall L.
    Arzneimittelforschung; 1985 Oct 05; 35(8):1227-31. PubMed ID: 2866774
    [Abstract] [Full Text] [Related]

  • 19. Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits.
    Ongini E, Bo P, Dionisotti S, Trampus M, Savoldi F.
    Psychopharmacology (Berl); 1992 Oct 05; 107(2-3):236-42. PubMed ID: 1352054
    [Abstract] [Full Text] [Related]

  • 20. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO, Rosén L, Fuxe K.
    Neuroscience; 1994 Jul 05; 61(2):269-83. PubMed ID: 7969908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.